Analytical Study for the Clinical Trials Law no. 214/2020 Guided by the International Declarations and Comparative Laws

The emergence of the Clinical Trials Law No. 214/2020 to the light was a very important step that was long overdue due to the vitality of the subject of clinical trials as it affects the infallibility of the human body and due to the development of medical sciences and the struggle between major companies to come up with new treatments that need to be tested on humans, and of course developing countries that do not regulate these experiments by legislation are an attractive arena for them to conduct these experiments without deterrence from the law or oversight from the concerned authorities in the state.

A preliminary reading of the texts of this law has rightly revealed the existence of some criticisms that can be directed to the texts of the law, which can negatively affect the effectiveness of this law and its good application.

In this research, I have analyzed and criticized some legal texts that cause confusion in their application or because of their ambiguity and lack of clarity in the scope of their application. Our goal is to help the legislator achieve the desired goal of the law, which is to organize clinical trials and research to the fullest extent to ensure the safety of the research subjects and a desire to overcome the mechanisms of scientific research that must be followed in order to reach new drug discoveries.

The study concluded that, despite the presence of some defects that require the intervention of the legislator to amend them and the existence of some other problems that can be solved and remedied by stipulating it in the executive regulations of the law when it is issued, it is worthy for the legislator to intervene in a timely manner -due to Corona pandemic vaccines- by issuing this law.